UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT ~~REPORTPursuant~~REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September ~~August 28~~10, 2012

MABCURE INC.
(Exact name of registrant as specified in its charter)

Nevada (State or other jurisdiction of of incorporation)

333-141131 (Commission File Number) 20-4907813 (IRS Employer Identification No.)

20-4907813(IRS Employer Identification No.)

21 Sparrow Circle
White Plains, NY 10605
(Address of principal executive offices and Zip Code)

(845) 591-3144 (Registrant's telephone number, including area code)

228 Park Ave S #15740 New York, NY 10003 (Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a -12)

[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))

[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))


Item 5.02	Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers

On August 2829, 2012, Mr. Dov Weinberg, the outsourced CFO of the Registrant who has not been duly authorized to file Forms 8-K on behalf of the Registrant, purported to file a Form 8-K reporting a change in the Board of Directors of the Registrant. The August 29, 2012 Form 8-K stated that at a meeting of the Board of Directors held on August 28, 2012, the Board of Directors approved the appointment of Dr.Charles T. Tackney to its Board of Directors. However, the August 28, 2012 meeting of the Board of Directors was not convened in accordance with the by-laws of the Registrant and therefore all actions taken at such unauthorized Board meeting are null and void and of no effect. The Form 8-K dated August 29, 2012 is therefore invalid and should be disregarded.

~~Dr.~~Relevant ~~Charles~~Factual T.Background: ~~Tackney,~~The ~~Ph.D.,~~registrant is currently attempting ~~the~~to ~~company's~~raise ~~Chief Scientific~~capital ~~Officer~~for ~~(CSO),~~its isworking acapital ~~scientific~~needs and ~~Business~~has ~~leader~~received ~~with diverse~~two ~~experience~~competing inoffers ~~clinical~~from ~~medicine~~existing ~~and~~shareholders ~~new~~of ~~technology~~the ~~development~~Company. ~~His~~One ~~background and~~of ~~expertise~~the ~~span~~three members of the ~~areas~~Registrant’s ofBoard ~~molecular~~is ~~biology,~~an ~~biotechnology~~interested ~~and diagnostics.~~director ~~Dr.~~because ~~Tackney~~of ~~has~~the director’s ~~served~~affiliation aswith the ~~Chief~~entity ~~Scientific~~that ~~Officer~~submitted one of ~~NeuroMark Genomics,~~the ~~Inc~~financing offers., ~~and~~The ~~prior~~remaining totwo ~~that,~~directors heare ~~worked~~at inan ~~various~~impasse ~~positions~~regarding ~~for~~pursuit ~~the~~of ~~Ortho~~one ~~Clinical~~of ~~Diagnostics~~the ~~unit~~two offinancing ~~Johnson~~offers. &In ~~Johnson,~~an ~~including,~~attempt ~~Director~~to ofcreate ~~the Diagnostic~~a ~~Biomarker~~“disinterested ~~Evaluation Group~~majority”, a ~~Scientific~~meeting ~~Director~~was ofpurportedly ~~Advanced~~called ~~Research &~~to ~~Technology~~appoint ~~Assessment~~another ~~World~~disinterested ~~Wide~~director, thereby asbreaking ~~well~~the asimpasse. ~~Director~~However, ofthis ~~the~~purported ~~Prion Research~~appointment ~~Group.~~and ~~He was~~ the underlying ~~Director~~board ofmeeting ~~Molecular~~were ~~Biology~~done ~~for~~in ~~ImClone~~contravention ~~Systems~~of at the ~~time~~Registrant’s ofby-laws. A ~~its~~report ~~founding,~~on ~~and~~Form 8-K was athen ~~Damon~~filed ~~Runyon~~without ~~Post-Doctoral~~the ~~Fellow~~approval ator participation of the ~~Columbia~~registrant’s ~~University~~Principal ~~Hammer~~Executive ~~Cancer~~Officer, ~~Center.~~who Hewas ~~received~~not ~~his~~present ~~Ph.D.~~at ~~from~~ the ~~City~~purported ~~University~~Board ~~of New York~~meeting.

There are no family relationships between any of our Directors or executive officers.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

MABCURE INC. (Registrant) ~~By: /s/Dov Weinberg Dov Weinberg Chief Financial Officer~~

~~Date~~By: ~~August~~/s/ 29Dr. ,Amnon Gonenne President ~~2012~~and CEO Chairman of the Board

Date: September 10, 2012

Filing Compare · MABCURE INC.